

Galectin Therapeutics Corporate Fact Sheet

Galectin Therapeutics, Inc. (NASDAQ: GALT) is the leading developer of compounds that target galectin proteins to treat fibrosis and cancer. Building upon GR-MD-02's broad activity in galectin-dependent animal models and robust activity in human disease, the company's primary focus is on NASH (non-alcoholic steatohepatitis) with advanced fibrosis and cirrhosis.

GR-MD-02 has demonstrated efficacy in moderate-to-severe plaque psoriasis, a human disease that is associated with NASH. Galectin is also pursuing GR-MD-02 combination immuno-therapy in advanced melanoma with Phase 1b trials underway with both Yervoy® and Keytruda®.

Galectin's CEO provides regular updates on its work and therapeutic area via a blog entitled CEO Perspectives, found at <http://perspectives.galectintherapeutics.com/>.

Investor Highlights

NASH is a potentially \$35 - \$40 billion global market and is one of the largest remaining opportunities with no current effective treatments


It is estimated that worldwide, one in four humans are affected by fatty liver disease (FLD), which translates into a potential global market of \$35 - \$40 Billion by 2025, based on current rates of FLD progression to NASH. There are currently no approved therapies for NASH.

Recent acquisitions suggest this is a highly valuable market

Allergan's (NYSE: AGN) \$1.7 Billion acquisition of Tobira, which has active NASH/Fatty Liver Disease clinical trials underway, demonstrate NASH is one of the last remaining very large, attractive, and untapped global markets for greenfield new drug development.


Galectin Phase 2 trial in NASH cirrhosis leads all competitors

Galectin's Phase 2 trial in NASH cirrhosis will report top line data in December, 2017.



NASH-CX Phase 2b Clinical Trial to read out December 2017

Enrollment was completed a month early, and as of January 2017 over 70% of total drug doses for the study have been administered. An independent data safety monitoring board (DSMB) found no safety concerns after evaluating 50% of subjects completing 6 months of therapy, which is consistent with the safety results from the Company's NASH-FX trial.



Fundamental Science on Target is Strong

Galectin-3 is critically important in the development of organ fibrosis. GR-MD-02 has demonstrated broad activity in galectin-dependent animal models and robust activity in human disease (moderate-to-severe plaque psoriasis). GR-MD-02 also has a differentiated profile from other classes of drugs: it **reverses** fibrosis.

Patent protection through 2031

Galectin has multiple U.S. and international patents. GR-MD-02 has two compositions-of-matter and five methods patents. Claims cover therapeutic formulations for use in the treatment of NASH, cancer and fibrotic, inflammatory and autoimmune disorders in which galectin proteins are involved. Additional patents pending.

GR-MD-02 demonstrates immunomodulation activity in preclinical models

In mice, GR-MD-02 boosted antitumor immunity, reduced tumor size and increased survival. Galectin hypothesizes that GR-MD-02 may be a complementary therapy to enhance efficacy of immune checkpoint blockade therapies in patients with melanoma, thus, increasing survival.

Management team with significant relevant experience

Peter G. Traber, M.D., President, CEO and CMO, has nearly 30 years of experience in research and development, clinical medicine and business development experience at GlaxoSmithKline and as Chairman of Medicine at the University of Pennsylvania, as well as CEO of Baylor College of Medicine. COO Harold Shlevin, Ph.D. has 30+ years of drug development and commercialization experience.

About Galectins and the GR-MD-02 Clinical Trials

Galectins are proteins that are normally expressed in small amounts in many different cell types, yet they are most highly expressed in macrophages of the immune system. Secreted galectins are markedly increased and have important roles in a wide variety of pathological processes involved in immune regulation, inflammation, fibrogenesis and tumor cell biology. GR-MD-02 is a complex carbohydrate proprietary drug that promotes galectin inhibition by binding to galectin-3, which is increased in inflammation, fibrogenesis and tumor formation. GR-MD-02 received FDA Fast Track designation. A Phase 1 study in NASH patients with advanced fibrosis showed GR-MD-02 was safe and well-tolerated and reached targeted doses. Proof of clinical efficacy in human disease was observed in a psoriasis study (psoriasis is associated with NASH) in which all of the patients treated in a Phase 2a open label trial showed improvement in disease activity by an average of 50%, with the greatest improvement being 82%. In cancer immunotherapy, a substantial unmet medical need remains in melanoma and multiple other cancers. Combination therapies might benefit from GR-MD-02, as it can inhibit secretions of galectin-3 by cancer cells that reduce the ability of the immune system to fight cancer.

Growth Strategy

- Capitalize on significant “head start” in clinical trials in \$35+ billion NASH cirrhosis market by advancing GR-MD-02 through NASH-CX Phase 2b trials and remaining on track to report top line data in December 2017.
- Leverage GR-MD-02’s demonstrated broad activity in galectin-dependent animal models and robust activity in human disease as a platform technology that can be expanded into adjacent markets.
- Support the completion of Phase 1b combination trials with GR-MD-02 in advanced melanoma and other cancers and secure a partnership to conduct later-stage clinical trials.
- Seek partner to accelerate the advancement of the discovery on new compounds for skin disease indications.
- Continue to pursue the potential for GR-MD-02 as a platform technology to treat other cancer types, as well as galectin-3-dependent lung, liver, and cardiovascular disease.

The information contained herein was obtained from Galectin Therapeutics management and other sources Gregory Communications believes to be reliable. This does not constitute the solicitation of the purchase or sale of securities. Gregory Communications has been engaged by Galectin Therapeutics as its investor relations firm. Except for historical information contained herein, matters discussed in this document are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Please see Galectin Therapeutics’ most recent Form 10-K and Forms 10-Q as filed with the U.S. Securities and Exchange Commission for additional information about the company and related risks.